

PATENT
ATTORNEY DOCKET NUMBER: 50036/016003

Certificate of Mailing	
Date of Deposit <u>July 20, 2001</u>	Label Number: <u>EL790829747US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Guy Beardsley</u> Printed name of person mailing correspondence	<u><i>Guy Beardsley</i></u> Signature of person mailing correspondence

11011 U.S. PTO
09/10518
07/20/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Philip W. Hammond et al.	Art Unit:
Serial No.:	Not yet assigned	Examiner:
Filed:	July 19, 2001	Customer No.: 21559
Title:	METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3'-UNTRANSLATED REGIONS AND OPTIMIZING CELLULAR RNA-PROTEIN FUSION FORMATION	

Assistant Commissioner For Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 09/374,962, filed on August 16, 1999. The following references cited on the PTO 1449 form were submitted to and/or cited by the Office in the prior application and, therefore, are not provided in this application


Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

If there are any other charges, or any credits, please apply them to Deposit

Account No. 03-2095.


Respectfully submitted,

Date: 20 July 2001


Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\\Clark-w2k1\documents\50036\50036.016003 IDS.wpd



21559

PATENT TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50036/016003

Serial No.

Not yet assigned

Applicant

Philip W. Hammond et al.

Filing Date

July 20, 2001

Group

IDS Filed

July 20, 2001

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,627,024	5/6/97	Maruyama et al.			
	5,643,768	7/1/97	Kawasaki			
	5,789,208	8/4/98	Sharon			
	5,985,575	11/16/99	Wickens et al.			
	5,849,878	12/15/98	Cantor et al.			
	5,965,133	10/12/99	Cantor et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 98/31700	07/23/98	PCT			
	WO 99/51773	10/14/99	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Capecchi, "Polypeptide Chain Termination In Vitro: Isolation of a Releasable Factor," Proc. Natl. Acad. Sci. 58:1144-1151 (1967)
	Capecchi and Klein, "Release Factors Mediating Termination of Complete Proteins," Nature 226:1029-1033 (1970)
	Drugeon et al., "Eukaryotic Release Factor 1 (eRF1) Abolishes Readthrough and Competes with Suppressor tRNAs at all Three Termination Codons in Messenger RNA," Nucl. Acids Res. 25:2254-2258 (1997)
	Frolova et al., "A Highly Conserved Eukaryotic Protein Family Possessing Properties of Polypeptides Chain Release Factor," Nature 372:701-703 (1994)
	Frolova et al., "Mammalian Polypeptide Chain Release Factor and Tryptophanyl-tRNA Synthetase are Distinct Proteins," The EMBO Journal 12:4013-4019 (1993)
	Higuchi, "Using PCR to Engineer DNA," Stockton Press, Chapter 6, pgs. 61-70, 1989
	Frolova et al., "Eukaryotic Polypeptide Chain Release Factor eRF3 is an eRF1- and Ribosome-Dependent Guanosine Triphosphatase," RNA 2:334-341 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50036/016003 Serial No. Not yet assigned Applicant Philip W. Hammond et al. Filing Date July 20, 2001 Group IDS Filed July 20, 2001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
(37 CFR §1.98(b))		
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
	Ilan, "Release Factor Regulating Termination of Complete Protein in a Eukaryotic Organism," J. Mol. Biol. 77:437-448 (1973)	
	Kisselev and Frolova, "Termination of Translation in Eukaryotes," Biochem. Cell Biol. 73:1079-1086 (1995)	
	Miyamoto-Sato et al., "Specific Bonding of Puromycin to Full-Length Protein at the C-Terminus," Nucl. Acids Res. 28:1176-1182 (2000)	
	Niemeyer et al., "Oligonucleotide-Directed Self-Assembly of Proteins: Semisynthetic DNA - Streptavidin Hybrid Molecules as Connectors for the Generation of Macroscopic Arrays and the Construction of Supramolecular Bioconjugates," Nucl. Acid Res. 22:5530-5539 (1994)	
	Roberts et al., "RNA-Peptide Fusions for the in vitro Selection of Peptides and Proteins," Proc. Natl. Acad. Sci. USA, 94:12297-12302, 1997	
	Singer et al., "Libraries for Genomic SELEX," Nucl. Acids Res. 25:781-786 (1997)	
	Stansfield et al., "The Products of the SUP45 (eRF1) and SUP35 Genes Interact to Mediate Translation Termination in Saccharomyces Cerevisiae," The EMBO J. 14:4365-4373 (1995)	
	Stansfield et al., "Depletion in the Levels of the Release Factor eRF1 Causes a Reduction in the Efficiency of Translation Termination in Yeast," Mol. Microbiol. 20:1135-1143 (1996)	
	Zhouravleva et al., "Termination of Translation in Eukaryotes is Governed by Two Interacting Polypeptide Chain Release Factors, eRF1 and eRF3," The EMBO J. 14:4065-4072 (1995)	
	Zozulya et al., "Mapping Signal Transduction Pathways by Phage Display," Nature Biotech. 17:1193-1198 (1999)	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		